Detalles de la búsqueda
1.
Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
Diabetes Obes Metab
; 26(5): 1799-1807, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38468125
2.
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
Diabetes Obes Metab
; 25(11): 3347-3355, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37580972
3.
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.
Diabetes Obes Metab
; 24(10): 1998-2007, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35670659
4.
Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
Diabetes Obes Metab
; 23(10): 2269-2278, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34142429
5.
Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
Diabetes Obes Metab
; 23(9): 2090-2098, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34047449
6.
Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
Diabetes Obes Metab
; 23(6): 1272-1281, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528904
7.
Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
Diabetes Obes Metab
; 21(3): 715-719, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30414260
8.
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes.
Diabetes Obes Metab
; 20(9): 2064-2074, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29707875
9.
Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.
Kidney Int
; 87(3): 649-59, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25229335
10.
Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial.
BMC Health Serv Res
; 13: 71, 2013 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23433347
11.
Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: a systematic review and meta-analysis.
EClinicalMedicine
; 62: 102119, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37593226
12.
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
Diabetes Ther
; 14(2): 377-386, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36574199
13.
Are nocturnal hypoglycemia prevention strategies influenced by diabetes technology usage? A BETTER registry analysis.
Diabetes Res Clin Pract
; 191: 110080, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36099973
14.
Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
J Med Econ
; 25(1): 238-248, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094622
15.
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
Nat Med
; 28(6): 1269-1276, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35551290
16.
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
BMJ Open Diabetes Res Care
; 10(2)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35383100
17.
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.
Can J Cardiol
; 38(8): 1153-1167, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961754
18.
The Canadian LMC Diabetes Registry: A Profile of the Demographics, Management, and Outcomes of Individuals with Type 1 Diabetes.
Diabetes Technol Ther
; 23(1): 31-40, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32667835
19.
A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Lancet Digit Health
; 3(11): e723-e732, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34580055
20.
Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
Can J Diabetes
; 45(8): 734-742, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33888413